S

Sheffield Children's NHS Foundation Trust | Sheffield Children's Hospital - Clinical Research Facility

Research site

(Unclaimed)

Location

Sheffield Children's Hospital, Sheffield, Sheffield, England

Site insights

Top conditions

Top treatments

Epidiolex

BMN 111

PF-04965842

Posoleucel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex (EpiCom)

The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1...

Enrolling

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Drug: Cannabidiol Oral Solution [Epidiolex]

Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta (Orbit)

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs...

Active, not recruiting

Osteogenesis Imperfecta

Other: Placebo

Biological: Setrusumab

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg